Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 7 studies | 26% ± 7% | |
B cell | 6 studies | 20% ± 4% | |
dendritic cell | 5 studies | 29% ± 9% | |
epithelial cell | 5 studies | 29% ± 13% | |
regulatory T cell | 5 studies | 19% ± 1% | |
natural killer cell | 4 studies | 18% ± 3% | |
classical monocyte | 4 studies | 23% ± 5% | |
conventional dendritic cell | 4 studies | 25% ± 10% | |
pericyte | 4 studies | 20% ± 4% | |
endothelial cell of lymphatic vessel | 3 studies | 24% ± 5% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 20% ± 4% | |
non-classical monocyte | 3 studies | 34% ± 8% | |
memory B cell | 3 studies | 19% ± 3% | |
endothelial cell of vascular tree | 3 studies | 18% ± 2% | |
basal cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2521.09 | 1445 / 1445 | 100% | 40.10 | 183 / 183 |
ovary | 100% | 1748.87 | 180 / 180 | 100% | 35.96 | 430 / 430 |
skin | 100% | 1991.15 | 1809 / 1809 | 100% | 50.91 | 472 / 472 |
thymus | 100% | 2393.62 | 653 / 653 | 100% | 48.67 | 605 / 605 |
uterus | 100% | 2023.00 | 170 / 170 | 100% | 58.56 | 459 / 459 |
lung | 100% | 3013.38 | 578 / 578 | 100% | 50.42 | 1154 / 1155 |
liver | 100% | 1548.68 | 226 / 226 | 100% | 33.24 | 405 / 406 |
stomach | 100% | 2132.01 | 359 / 359 | 100% | 46.28 | 285 / 286 |
intestine | 100% | 3163.75 | 966 / 966 | 100% | 54.90 | 525 / 527 |
prostate | 100% | 2549.33 | 245 / 245 | 100% | 48.38 | 500 / 502 |
kidney | 100% | 3122.90 | 89 / 89 | 100% | 39.14 | 897 / 901 |
bladder | 100% | 2890.33 | 21 / 21 | 99% | 62.34 | 501 / 504 |
breast | 100% | 2602.61 | 459 / 459 | 99% | 43.11 | 1109 / 1118 |
pancreas | 99% | 1240.45 | 324 / 328 | 100% | 65.08 | 178 / 178 |
adrenal gland | 100% | 1790.90 | 258 / 258 | 98% | 26.48 | 226 / 230 |
brain | 79% | 629.60 | 2086 / 2642 | 100% | 43.99 | 704 / 705 |
adipose | 100% | 2862.23 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 48.93 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 98.47 | 29 / 29 |
spleen | 100% | 3102.72 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 60.23 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 39.46 | 1 / 1 |
blood vessel | 100% | 2197.78 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2229.81 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 100% | 1640.75 | 857 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 2372.93 | 899 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050871 | Biological process | positive regulation of B cell activation |
GO_0023035 | Biological process | CD40 signaling pathway |
GO_2000352 | Biological process | negative regulation of endothelial cell apoptotic process |
GO_0006954 | Biological process | inflammatory response |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0034138 | Biological process | toll-like receptor 3 signaling pathway |
GO_0070498 | Biological process | interleukin-1-mediated signaling pathway |
GO_0043032 | Biological process | positive regulation of macrophage activation |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0050821 | Biological process | protein stabilization |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0006915 | Biological process | apoptotic process |
GO_0034134 | Biological process | toll-like receptor 2 signaling pathway |
GO_0034162 | Biological process | toll-like receptor 9 signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TNIP2 |
Protein name | TNFAIP3 interacting protein 2 TNFAIP3-interacting protein 2 (A20-binding inhibitor of NF-kappa-B activation 2) (ABIN-2) (Fetal liver LKB1-interacting protein) |
Synonyms | ABIN2 FLIP1 |
Description | FUNCTION: Inhibits NF-kappa-B activation by blocking the interaction of RIPK1 with its downstream effector NEMO/IKBKG. Forms a ternary complex with NFKB1 and MAP3K8 but appears to function upstream of MAP3K8 in the TLR4 signaling pathway that regulates MAP3K8 activation. Involved in activation of the MEK/ERK signaling pathway during innate immune response; this function seems to be stimulus- and cell type specific. Required for stability of MAP3K8. Involved in regulation of apoptosis in endothelial cells; promotes TEK agonist-stimulated endothelial survival. May act as transcriptional coactivator when translocated to the nucleus. Enhances CHUK-mediated NF-kappa-B activation involving NF-kappa-B p50-p65 and p50-c-Rel complexes. . |
Accessions | ENST00000503235.1 Q8NFZ5 D6RGJ2 ENST00000510267.5 [Q8NFZ5-2] ENST00000315423.12 [Q8NFZ5-1] |